Updated
- Log In
- Newsletters
-
Subscribe
Access insights and guidance from our Wall Street pros. Find the product that's right for you.
Pharmaceuticals
Gilead Sciences Names Roche's O'Day as CEO and Chairman
Daniel O'Day will take over the helm of the biopharmaceutical giant on March 1, 2019.
Abbott, Glaxo, Casella and More: 'Mad Money' Lightning Round
Jim Cramer weighs in on Abbott, GlaxoSmithKline, Waste Management and more.
CVS Health to Roll Out New Drug Pricing Model
The new model will allow CVS Caremark to pass through 100% of drug rebates to its health plan clients.
Pfizer Is in Breakout-Mode This Fall: Chart
This healthcare stock looks healthy for your portfolio amid the volatility.
Bristol-Myers Drops After Lung-Cancer Drug Study Fails
Shares decline after the company says a lung-cancer study it had been working on failed.
Tech Selloff Could Work in Favor of Pharmaceutical Stocks
Pharma could be the best parking spot for your money if the market keeps trending downward.
Pfizer Shares Rise Even as U.S. Lawmakers, Administration Criticize Drug Pricing
Shares of the New York City-based pharmaceutical giant are rising on Monday.
Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth
The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.
Jim Cramer Reacts to Pfizer's Drug Hikes
Jim Cramer responds to the news that the drug company, Pfizer, has hiked rates.
Here's a Handful of Ways to Navigate Biotech's Choppy Seas
Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.